Tirzepatide
US$ 21.70
activate glp 1 hormone glp-1_ra_pharmacology [TUSOM Glucagon-Like Peptide-1 Receptor Agonists And
Description
North America dominates the market with share of 73% CAGR in 2022, and is anticipated to grow with 17% CAGR over the forecast period 2023-2029
This medication has quickly become a prominent name in the health and wellness space, but its roots go back several years through rigorous clinical testing
Its kept that title for years
Anyone expecting dramatic results should temper expectations
Brown JC, Mutt V, Pederson RA
